🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 52 of 116

  1. IRINOTECAN, FOLINIC ACID, FLUOROURACIL, DOMVANALIMAB, FLUOROURACIL, ZIMBERELIMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    stomach cancer, Esophage, gastro-oesophageal junction adenocarcinoma

    phase 2 small molecule active

    1 trial

  2. IRINOTECAN, lurbinectedin

    Lacuna Pharma Pty Ltd

    Selected Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  3. ISA101b

    Regeneron UK Limited

    Squamous Cell Carcinoma of the Oropharynx

    phase 2 mab active

    2 trials

  4. ISIS 2503

    IONIS PHARMACEUTICALS INC

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  5. ISIS EIF4E Rx

    IONIS PHARMACEUTICALS INC

    Castrate-Resistant Prostate Cancer

    phase 2 small molecule completed

    1 trial

  6. ISIS EIF4E Rx

    IONIS PHARMACEUTICALS INC

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  7. IXAZOMIB

    Takeda

    Follicular Lymphoma

    phase 2 small molecule completed

    1 trial

  8. Ibrutinib

    Karyopharm Therapeutics Inc

    Lymphoma

    phase 2 small molecule active

    1 trial

  9. Ibrutinib 560 mg

    United Therapeutics Europe Ltd

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  10. Iclusig 15 mg film-coated tablets

    Ningbo Cancer Hospital

    Chronic myelogenous leukemia

    phase 2 small molecule active

    1 trial

  11. Iclusig 15 mg film-coated tablets, BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion., Imatinib TAD 400 mg επικαλυμμένα με λεπτό υμένιο δισκία

    Cardiff Oncology

    Blood cancer

    phase 2 small molecule active

    1 trial

  12. Iclusig 15 mg film-coated tablets, Iclusig 45 mg film-coated tablets, Ponatinib, Iclusig 15 mg film-coated tablets, Iclusig 15 mg film-coated tablets, Iclusig 30 mg film-coated tablets., Ponatinib, Iclusig 45 mg film-coated tablets, Ponatinib

    Incyte

    Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors

    phase 2 small molecule active

    1 trial

  13. Iclusig 30 mg film-coated tablets, Iclusig 45 mg film-coated tablets, Iclusig 45 mg film-coated tablets, Iclusig 15 mg film-coated tablets, Iclusig 15 mg film-coated tablets, Iclusig 15 mg film-coated tablets, Ponatinib

    Takeda

    Chronic Phase Chronic Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  14. Icotinib

    The First People's Hospital of Lianyungang

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  15. Icotinib

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  16. Idasanutlin

    Hoffmann-La Roche

    Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial

  17. Ifetroban Sodium

    CUMBERLAND PHARMACEUTICALS INC

    Malignant Solid Tumor

    phase 2 small molecule active

    1 trial

  18. Ifinatamab Deruxtecan

    Merck Sharp and Dohme

    Esophageal squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  19. Ifinatamab Deruxtecan, DOCETAXEL , Raludotatug Deruxtecan

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  20. Ifinatamab deruxtecan

    Daiichi Sankyo

    Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  21. Ifinatamab deruxtecan

    Daiichi Sankyo

    Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and cutaneous melanoma)

    phase 2 small molecule active

    1 trial

  22. Imgatuzumab

    Centessa Pharmaceuticals plc

    Cutaneous Squamous Cell Carcinoma

    phase 2 small molecule terminated

    1 trial

  23. Immunological Agent

    The First People's Hospital of Lianyungang

    Lung Cancer Metastatic

    phase 2 small molecule active

    1 trial

  24. Immunomodulatory DC vaccines to target prostate cancer

    Shenzhen Second People's Hospital

    Prostate Cancer Indications

    phase 2 mab active

    1 trial

  25. Immunotherapy combined with chemotherapy

    The First People's Hospital of Lianyungang

    Rectal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  26. Imnovid 4 mg hard capsules, JAMP Pomalidomide, Pomalidomide Adalvo 3 mg hard capsules, Imnovid 1 mg hard capsules, Imnovid 4 mg hard capsules, Pomalidomide Adalvo 1 mg hard capsules, Imnovid 2 mg hard capsules, JAMP Pomalidomide, Imnovid 1 mg hard capsules, JAMP Pomalidomide, Dexamethason 4 mg JENAPHARM®, Imnovid 3 mg hard capsules, Pomalidomide Adalvo 4 mg hard capsules, Pomalidomide Adalvo 2 mg hard capsules, Dexamethason 8 mg JENAPHARM®, Isatuximab, Isatuximab, JAMP Pomalidomide, Imnovid 3 mg hard capsul

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  27. Imx-110

    Immix Biopharma

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  28. Indibulin

    Alaunos Therapeutics

    Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  29. Induction Therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN

    phase 2 small molecule active

    1 trial

  30. Induction of neo-antigen specific T cells by specialized cross-presenting dendritic cells in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy, the NEODOC study

    Disc Medicine

    Ovarian cancer

    phase 2 other active

    1 trial

  31. Induction therapy of GP(Pomalidomide+Obinutuzumab）

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Indolent Lymphoma

    phase 2 small molecule active

    1 trial

  32. Inetetamab

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  33. Inflectra 100 mg powder for concentrate for solution for infusion, Inflectra 100 mg powder for concentrate for solution for infusion, AZD0171, Oleclumab, Mycophenolate Mofetil 250 mg Capsules, Inflectra 100 mg powder for concentrate for solution for infusion, CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion., volrustomig, CISPLATIN , Monalizumab, Datopotamab deruxtecan, Inflectra 100 mg powder for concentrate for solution for infusion, Rilvegostomig, Inflectra 100 mg powder for concentra

    AstraZeneca AB

    Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  34. Iniparib

    Sanofi Pasteur

    Breast Cancer, Metastatic

    phase 2 small molecule completed

    1 trial

  35. Injection of humanized nerve growth factor (NGF) antibody

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Cancer Pain

    phase 2 small molecule active

    1 trial

  36. Inotuzumab Ozogamicin±Donor Lymphocyte Infusion

    The First People's Hospital of Lianyungang

    Leukemia, Lymphocytic, Acute

    phase 2 small molecule active

    1 trial

  37. Inotuzumab ozogamicin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  38. Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone.

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  39. Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer

    The George Institute

    Ovarian Cancer

    phase 2 other active

    1 trial

  40. Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells

    The First People's Hospital of Lianyungang

    B Cell Lymphoma

    phase 2 mab active

    1 trial

  41. Intermittent PD-1/PD-L1 ICI + VEGFR-TKI

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Renal Cell Carcinoma (RCC)

    phase 2 small molecule active

    1 trial

  42. Intismeran autogene

    Merck KGaA, Darmstadt, Germany

    Malignant Melanoma

    phase 2 mab active

    1 trial

  43. Intrathecal Administration of Thiotepa in Combination with Trastuzumab via the Ommaya Reservoir

    The First People's Hospital of Lianyungang

    Leptomeningeal Metastasis of HER2-positive Breast Cancer

    phase 2 small molecule active

    1 trial

  44. Intravenous esketamine using Dixon's up-and-down sequential method

    The First People's Hospital of Lianyungang

    Hepatic Neoplasm

    phase 2 small molecule active

    1 trial

  45. Iodine-124

    United Therapeutics Europe Ltd

    Thyroid Cancer

    phase 2 small molecule active

    1 trial

  46. Iomab-B

    Actinium Pharmaceuticals

    Non Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  47. Iparomlimab and Tuvonralimab Injection (QL1706)

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  48. Iparomlimab and Tuvonralimab Injection (QL1706)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cholangiocarcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.